

Article Info



Article Type:

Letter to the Editor

Article History:

Received: 26 Sep. 2025

Revised: 2 Nov. 2025

Accepted: 4 Nov. 2025

ePublished: 22 Nov. 2025



Spirulina: A promising opportunity to overcome neuropathic pain challenges in chronic kidney disease patients

Zahra Nazari Taloki^{1,2*}

¹Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

²Department of Clinical Pharmacy, School of Pharmacy, Babol University of Medical Sciences, Babol, Iran

To Editor,

Neuropathic pain management presents significant challenges due to its multifactorial etiology and complex underlying pathways. This is particularly evident in patients with chronic kidney disease (CKD), who require meticulous drug selection and dose adjustment to avoid further renal compromise. Peripheral polyneuropathy is the most prevalent complication associated with CKD, affecting over 60% of patients and contributing to disability and diminished quality of life.¹ First-line treatments for neuropathic pain syndromes, including tricyclic antidepressants, gabapentinoids, and serotonin-norepinephrine reuptake inhibitors, are commonly recommended. However, the inherent complexity of neuropathic pain and the poor tolerability of these medications in CKD patients underscore the growing need for novel therapeutic agents.²

Spirulina, a filamentous cyanobacterium, is rich in bioactive compounds such as phycocyanin, polyphenols, β -carotene, γ -linolenic acid, and antioxidant enzymes, including superoxide dismutase (SOD) and catalase. These constituents exhibit potent anti-inflammatory and antioxidant effects by inhibiting NF- κ B and COX-2 signaling pathways and reducing inflammatory cytokines like TNF- α and IL-6.³ The U.S. Food and Drug Administration (FDA) recognizes Spirulina as a safe dietary supplement.⁴ Nonetheless, caution is warranted regarding its potential interactions with cytochrome P450 isoenzymes.⁵

Emerging evidence suggests that Spirulina may offer benefits in ameliorating neuropathy. Preclinical studies have demonstrated its positive effects on diabetic neuropathy, sciatic neuropathic pain, and chemotherapy-induced neuropathy.⁶⁻⁸ Notably, dysregulation of

the Nrf2 pathway and oxidative stress are central to CKD progression and its complications. From a neuroprotective perspective, Spirulina activates Nrf2/HO-1 and BDNF/CREB signaling pathways, serving as a potential therapeutic target for neuropathic pain management by enhancing antioxidant defense, neuronal survival, and neurogenesis. It also suppresses microglial activation and inflammatory cytokines, thereby mitigating neuroinflammation and protecting neurons from oxidative stress-induced apoptosis.⁹⁻¹²

Numerous studies have further elucidated the nephroprotective properties of Spirulina. Its efficacy and safety in CKD patients have been substantiated.^{13,14} Specifically, Spirulina significantly reduces oxidative stress markers such as malondialdehyde (MDA) and reactive oxygen species (ROS), boosts antioxidant enzyme activity in renal tissue, inhibits inflammatory mediators including TNF- α , IL-6, and TGF- β implicated in renal inflammation and fibrosis, and modulates fibrosis and apoptosis pathways to protect against CKD progression.¹⁵

Together, these molecular mechanisms support spirulina's dual neuro- and nephroprotection potential in CKD patients experiencing neuropathic pain. Although it has not yet garnered widespread clinical attention, Spirulina's valuable nephroprotective and neuroprotective attributes merit further investigation as a novel, efficacious complementary treatment for neuropathy in this population. Robust validation through targeted clinical trials is imperative. We posit that Spirulina represents a promising avenue to enhance the quality of life for these patients. Your journal would lead innovative research by highlighting this strategy to address this pressing clinical challenge.

*Corresponding author: Zahra Nazari Taloki, Email: zahra_nazari_taloki@yahoo.com



Study Highlights

- Neuropathic pain is a complex challenge in chronic kidney disease (CKD) patients.
- Existing treatments often have limited efficacy and tolerance issues.
- Spirulina exhibits anti-inflammatory and antioxidant properties.
- This study highlights spirulina's dual neuroprotective and nephroprotective potentials in CKD patients.
- Molecular mechanisms include modulation of inflammatory cytokines and oxidative stress.
- Spirulina may provide a novel complementary treatment to improve quality of life in CKD patients.

Competing Interests

The author declares that she has no conflict of interest.

Ethical Approval

Not applicable.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

- Gondhali G, Kundalwal A, Takalkar AA. Peripheral neuropathy in chronic kidney diseases: prevalence and its correlates. *Int J Adv Med* **2020**; 7: 22-6. doi: 10.18203/2349-3933.ijam20195621
- Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. *Pain Ther* **2017**; 6: 35-42. doi: 10.1007/s40122-017-0087-0
- Mousavi S, Yegdaneh A, Shirani M, Feizi A, Ghanadian M. *Spirulina* supplementation and its effects on inflammation and oxidative stress: a systematic review and meta-analysis on randomized clinical trials. *J Funct Foods* **2025**; 131: 106945. doi: 10.1016/j.jff.2025.106945
- Dąbrowska NK, Marcinkowski K, Mazur A, Mazur S, Madera M, Strus K, et al. *Spirulina maxima* supplementation: benefits and limitations—results of latest studies. *J Pre Clin Clin Res* **2024**; 18:195-200. doi: 10.26444/jpcr/189444
- Savranoglu S, Tumer TB. Inhibitory effects of *Spirulina platensis* on carcinogen-activating cytochrome P450 isozymes and potential for drug interactions. *Int J Toxicol* **2013**; 32: 376-84. doi: 10.1177/1091581813503887
- Safakhah HA, Tamimi F, Moradi Kor N, Bandegi AR, Ghanbari A. Hypoalgesic effect of *Spirulina platensis* on the sciatic neuropathic pain induced by chronic constriction injury in male rats. *Biomed Res Ther* **2018**; 5: 2671-9. doi: 10.15419/bmrat.v5i9.477
- Ghosh M, Tasnim SF, Roy S, Ghash S, Sathi MN, Jahan N, et al. Effects of *Spirulina platensis* on hyperglycemia and mechanical allodynia in streptozotocin-induced diabetic rats: *Spirulina platensis* on hyperglycemia and mechanical allodynia. *Journal of the Medical College for Women & Hospital* **2024**; 20: 56-63. doi: 10.3329/jmcwh.v20i2.77290
- Le Gouill-Jaijart C, Péréon Y, Leroy M, Lépine O, Loloum A, Peluchon C, et al. PROPERTY: study protocol for a randomized, double-blind, multicenter placebo-controlled trial assessing neurotoxicity in patients with metastatic gastrointestinal cancer taking PHYCOCARE® during oxaliplatin-based chemotherapy. *Trials* **2023**; 24: 50. doi: 10.1186/s13063-023-07071-z
- Koh EJ, Seo YJ, Choi J, Lee HY, Kang DH, Kim KJ, et al. *Spirulina maxima* extract prevents neurotoxicity via promoting activation of BDNF/CREB signaling pathways in neuronal cells and mice. *Molecules* **2017**; 22: 1363. doi: 10.3390/molecules22081363
- Almeida T, Manfroi G, Silva S, Beggiora P, Schwingel D, Bertolin TE. Exploring the neuroprotective effects of *Spirulina platensis*: insights into hemorrhagic volume and histological outcomes. *Cureus* **2023**; 15: e42078. doi: 10.7759/cureus.42078
- Sorrenti V, Castagna DA, Fortinguerra S, Buriani A, Scapagnini G, Willcox DC. *Spirulina* microalgae and brain health: a scoping review of experimental and clinical evidence. *Mar Drugs* **2021**; 19: 293. doi: 10.3390/md19060293
- Aranda-Rivera AK, Cruz-Gregorio A, Pedraza-Chaverri J, Scholze A. Nrf2 activation in chronic kidney disease: promises and pitfalls. *Antioxidants (Basel)* **2022**; 11: 1112. doi: 10.3390/antiox11061112
- Rodríguez-Salgueiro S, Ramírez-Carmenate Z, González-Núñez L. An update on potential applications of *Spirulina* sp. and C-phycoerythrin to treat kidney diseases. *Ann Res Antioxid* **2017**; 2: e04.
- Memije-Lazaro IN, Blas-Valdivia V, Franco-Colín M, Cano-Europa E. *Arthrospira maxima* (*Spirulina*) and C-phycoerythrin prevent the progression of chronic kidney disease and its cardiovascular complications. *J Funct Foods* **2018**; 43: 37-43. doi: 10.1016/j.jff.2018.01.013
- Abouzeid TK, Soliman MM, Khatab SA, Gouda WM, Eldomany EB, Dorgham DA. The protective impacts of *Spirulina platensis* against cisplatin-induced renal injury through the regulation of oxidative stress, pro-inflammatory cytokines and Bax/Bcl2. *Toxicol Res (Camb)* **2022**; 11: 169-78. doi: 10.1093/toxres/tfab128